Represented Madrigal Pharmaceuticals (NasdaqGM: MDGL) in connection with its $35 million private placement offering, consisting of 1.97 million shares of Series A Convertible Preffered Stock and 328,300 shares of common stock. Investors included existing, non-controlling stockholders of Madrigal. The company expects to use the funds to continue its clinical studies for MGL-3196, a proprietary, liver-directed, selective thyroid hormone receptor- ß, for the treatment of non-alcoholic steatohepatitis (NASH), and for the development of other product candidates. Read the press release.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases.